Claims
- 1. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide encoding the polypeptide comprising amino acid −26 to amino acid 93 as set forth in SEQ ID NO:2; (b) a polynucleotide encoding the polypeptide comprising amino acid 1 to amino acid 93 as set forth in SEQ ID NO:2 (c) a polynucleotide which encodes a mature polypeptide having the amino acid sequence expressed by the DNA contained in ATCC Deposit No. 75703; (d) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a), (b) or (c); and (e) a polynucleotide fragment of the polynucleotide of (a) (b), (c) or (d).
- 2. The polynucleotide of claim 1 wherein the polynucleotide is DNA.
- 3. The polynucleotide of claim 2 which encodes the polypeptide comprising amino acid 1 to 93 of SEQ ID NO:2.
- 4. A vector containing the DNA of claim 2.
- 5. A host cell genetically engineered with the vector of claim 4.
- 6. A process for producing a polypeptide comprising: expressing from the host cell of claim 5 the polypeptide encoded by said DNA.
- 7. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of claim 4.
- 8. A polypeptide comprising a member selected from the group consisting of (i) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof; and (ii) a polypeptide encoded by the cDNA of ATCC Deposit No. 75703 and fragments, analogs and derivatives of said polypeptide.
- 9. The polypeptide of claim 8 wherein the polypeptide comprises amino acid 1 to amino acid 93 of SEQ ID NO:2.
- 10. A compound which inhibits activation of the polypeptide of claim 8.
- 11. A method for the treatment of a patient having need of MCP-4 comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 8.
- 12. The method of claim 11 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 13. A method for the treatment of a patient having need to inhibit an MCP-4 polypeptide comprising: administering to the patient a therapeutically effective amount of the compound of claim 10.
- 14. A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of MCP-4 comprising:
determining a mutation in a nucleic acid sequence encoding MCP-4.
- 15. A diagnostic process comprising:
analyzing for the presence of the polypeptide of claim 8 in a sample derived from a host.
- 16. A method for identifying compounds which bind to and inhibit activation of the polypeptide of claim 8 comprising:
contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound under conditions to permit binding to the receptor; and detecting the absence of a signal generated from the interaction of the compound with the receptor.
- 17. A method for identifying compounds which bind to and activate the polypeptide of claim 8 comprising:
contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound under conditions to permit binding to the receptor; and detecting the presence of a signal generated from the interaction of the compound with the receptor.
- 18. A method for increasing the amount of hematopoietic progenitor cells in the peripheral blood of a host comprising:
administering to the host the polypeptide of claim 8 in an amount effective to increase the amount of hematopoietic progenitor cells in the peripheral blood of the host.
- 19. A method for inhibiting destruction of hematopoietic progenitor cells resulting from the treatment of a host with a chemotherapeutic agent, comprising:
administering to the host the polypeptide of claim 8 in an amount effective to inhibit destruction of hematopoietic progenitor cells by a chemotherapeutic agent.
- 20. A method for inhibiting degeneration of neuronal cells in a host comprising:
administering to a host in need thereof the polypeptide of claim 8 in an amount effective to inhibit degeneration of the neuronal cells.
Parent Case Info
[0001] This application is a division of application Ser. No. 09/453,416, filed Dec. 3, 1999, which is a division of application Ser. No. 09/044,855, filed Mar. 20, 1998, now U.S. Pat. No. 6,100,389, which is a continuation-in-part of application Ser. No. 08/479,126, filed Jun. 7, 1995, now U.S. Pat. No. 5,866,373, which is a continuation-in-part of application Ser. No. 08/424,425, filed Apr. 21, 1995, and Application No. PCT/US94/05384, filed May 16, 1994, each of which disclosure is herein incorporated by reference.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09453416 |
Dec 1999 |
US |
Child |
10141965 |
May 2002 |
US |
Parent |
09044855 |
Mar 1998 |
US |
Child |
09453416 |
Dec 1999 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
08479126 |
Jun 1995 |
US |
Child |
09044855 |
Mar 1998 |
US |
Parent |
08424425 |
Apr 1995 |
US |
Child |
08479126 |
Jun 1995 |
US |
Parent |
PCT/US94/05384 |
May 1994 |
US |
Child |
08479126 |
Jun 1995 |
US |